Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
Article 2022 en
Authors
ΑA
Αngeliki Andrikopoulou
EZ
Eleni Zografos
KA
Kleoniki Apostolidou
Abstract
1 min read
Overall, genetic testing should be offered in most patients with ovarian cancer to identify mutations in HRR genes and determine the population that would be susceptible to poly ADP ribose polymerase (PARP) inhibitors.
Anna Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon P. Keam, Heather Thorne, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin J. Blyth, Declan G. Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phillip K. Darcy, Ygal Haupt, Scott Williams, Elena Castro, David Olmos, David L. Goode, Paul J. Neeson, Shahneen Sandhu
Tereza Vaclová, Nicholas T. Woods, Fernando Setién, José María García Bueno, José A. Macías, Alicia Barroso, Miguel Urioste, Manel Esteller, Álvaro N.A. Monteiro, Javier Benı́tez, Ana Osório
Johann S. de Bono, Maha Hussain, Antoine Thiery-Vuillemin, Joaquı́n Mateo, Oliver Sartor, Kim N., Karim Fizazi, Przemyslaw Twardowski, Neeraj Agarwal, Shahneen Sandhu, David Olmos, Neal D. Shore, Fred Saad, Sherry Liu, Carsten Goessl, Joe Burgents
Discussion(0)
No comments yet. Be the first to comment.